Danaher Corporation (DHR) Q4 2025 (USD): Adj EPS 2.23 (exp. 2.16), Revenue 6.84bln (exp. 6.80bln), Current FY EPS 7.80 (exp. 7.73), Next FY EPS 8.50 (exp. 8.42)

Danaher Corporation exceeded expectations with its Q4 2025 results, posting higher-than-expected adjusted EPS and revenue.

Newsquawk StaffPublished On the live feed at 6 more headlines followed before this page went public
Newsquawk headlinesUTC

Otis Worldwide Corporation (OTIS) Q4 2025 (USD): EPS 1.03 (exp. 1.04), Revenue 3.80bln (exp. 3.90bln)

Scotts Miracle-Gro (SMG) reportedly makes a deal to sell its cannabis-supply unit, via WSJ

Danaher Corporation (DHR) Q4 2025 (USD): Adj EPS 2.23 (exp. 2.16), Revenue 6.84bln (exp. 6.80bln), Current FY EPS 7.80 (exp. 7.73), Next FY EPS 8.50 (exp. 8.42)

Newsquawk Daily US Opening News - 28th January 2026

ASML (ASML NA) executive says recent announcements by AI/chip names will have a positive impact on the Co., references SK Hynix (000660 KS) and Micron (MU), among others

Open the platform and use it. The whole workspace is free to try, with no signup and no card. When you want the headlines arriving live instead of on a delay, Newsquawk Pro is £24.99 for 7 days.

Free. No signup, no card.
  • Biotechnology Revenue 2.03bln (exp. 2.03bln)
  • Life Sciences 2.09bln (exp. 2.07bln) 
Context

This performance not only beats estimates for the current fiscal year but also for FY 2026, suggesting strong operational momentum and potential bullish sentiment in the life sciences sector. The results may positively influence Danaher's stock and set a favorable tone for its peers in the biotechnology and life sciences space.

Related headlines

The whole workspace, free to try.

Try it free